ASPL’s work sits inside India’s established nuclear-science and healthcare frameworks.
The directions we work on — medical isotope production, accelerator-based BNCT, plasma-technology commercialisation — are already priorities in public Government of India roadmaps. We are one engineering expression of that direction, within existing regulatory and safety frameworks.
This page summarises the public policy frameworks and statutes within which our programme operates. Each is linked to its primary public source — we do not cite anything here that cannot be verified against the official document.
Mega Science Vision 2035 — Nuclear Physics (MSV2035)
Department of Science and Technology, Government of India · commissioned by the Principal Scientific Adviser · published 2023
MSV2035-NP is the Government of India’s decadal roadmap for nuclear-physics priorities. It specifies several capability directions that ASPL’s engineering programme supports: high-flux neutron sources for medical isotope production, accelerator-driven Boron Neutron Capture Therapy, commercialisation of plasma technologies through IPR, and explicit support for industry participation in mega-science projects.
The relevant sections are §2.7.1 (volumetric neutron sources), §3.3 (accelerator-driven BNCT), §4.2.1 (medical radioisotopes), §4.1.3 (accelerator-driven sub-critical systems), §4.2.4 (plasma-technology commercialisation), and §5.2(b) (industry participation mandate).
Our position: alignment is by direction, not by nomination. MSV2035 was written before our company was visible. The fact that national priorities and our engineering scope overlap is structural, and we treat it as such.
SHANTI Act 2025
Sustainable Harnessing and Advancement of Nuclear Energy for Transforming India · passed 17 December 2025 · in force 21 December 2025
The SHANTI Act replaces the earlier Civil Liability for Nuclear Damage framework and establishes a graded liability structure for nuclear operators in India. Together with the April 2025 amendments to the Atomic Energy Act, it provides the legal basis under which private entities may operate nuclear-adjacent infrastructure in defined categories — the first such opening in roughly six decades.
Our engineering documentation, facility design, and operational planning are being prepared within this framework — not around it.
Atomic Energy Regulatory Board (AERB)
Established under the Atomic Energy Act, 1962 · regulator for ionising radiation in India
AERB licenses radiation facilities, regulates radioactive-material transport, and sets the safety framework for accelerator-based neutron sources and associated facilities. Our engagement with AERB follows published guidance for Category-II source facilities — the appropriate classification for our near-term accelerator and early Gas Dynamic Trap operations — with a staged progression toward Category I as later phases require. Safety analysis, shielding design, operational procedures, and emergency-response planning are being prepared accordingly.
CDSCO and the medical-device pathway
Central Drugs Standard Control Organisation · regulator for drugs and devices in India
Any clinical application of our neutron-based platforms — particularly BNCT — passes through CDSCO’s medical-device and drug approval pathways, in addition to AERB clearance. We follow standard Indian regulatory practice and have not requested, nor do we assume, expedited treatment.
Nuclear Energy Mission & Viksit Bharat 2047
Government of India · publicly stated national policy
The Nuclear Energy Mission (announced with a ₹20,000 Cr allocation) and the Viksit Bharat 2047 per-capita energy targets set the long-horizon policy context for India’s nuclear infrastructure. Our work on medical isotopes and industrial neutron applications sits in the near-term portion of this horizon; applications with a fusion-energy component sit at the far end of a long staged program.
Institutional siting
Our incubation is at AIC Plasmatech, Gandhinagar — approximately five kilometres from the Institute for Plasma Research (IPR) and ITER-India, the largest concentration of plasma and fusion-engineering capability in the country. IPR’s FCIPT (Facilitation Centre for Industrial Plasma Technologies) operates from the same industrial estate. Siting matters for engineering and for safety culture; the Gandhinagar cluster is a working ecosystem we can engage with, not a logo on a slide.